Tue, Jan 27, 2015, 11:15 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Prana Biotechnology Limited Message Board

kadaicher1 270 posts  |  Last Activity: 4 hours ago Member since: Jan 23, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • kadaicher1 kadaicher1 4 hours ago Flag

    The AD development was always going to take a back seat to the HD development for PBT2. IMAGINE was never powered to demonstrate cognition and was mainly a biomarker trial. My guess is they will not drop it, because as far as I know, they have not reached dose limiting toxicity, or tried it in combination. I hope all resources are directed into HD and PD development. It will take a much larger trial to prove much in AD.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 4 hours ago Flag

    Thanks for that pivalde, maybe they are onto something there. Loss of B2-microglobulin can lead to excess iron build, a known feature of neurogegeneration.
    "β2 microglobulin associates not only with the alpha chain of MHC class I molecules, but also with class I-like molecules such as CD1 and Qa.

    An additional function is association with the HFE protein, together regulating the expression of hepcidin in the liver which targets the iron transporter ferroportin on the cytoplasmic membrane of enterocytes and macrophages for degradation resulting in decreased iron uptake from food and iron release from recycled red blood cells respectively. Loss of this function causes iron excess and hemochromatosis."

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 4 hours ago Flag

    Someone colored the end of the tape, but it was a good day considering the market.

    Sentiment: Strong Buy

  • Reply to

    Zn2+ and Memory Loss

    by interestingtome Jan 26, 2015 9:29 AM
    kadaicher1 kadaicher1 20 hours ago Flag

    Maybe, but PBT2 , although an analog of CQ, has some differences. I doubt PRAN would dare to change the dose till after the 2 yr safety results are in. Reactions were dose dependent in Euro, where they had two dose levels. The pre clinical data demonstrated dose dependency, and even the Lindquist paper identified highest MPAC efficacy right before toxicity.

    Sentiment: Strong Buy

  • Reply to

    price is very low, when do you buy?

    by kadaicher1 Jan 19, 2015 6:12 AM
    kadaicher1 kadaicher1 21 hours ago Flag

    They have nothing for AD while the AD trial is still running. Brilliant. They also have MPACs in development for several other conditions.

    Sentiment: Strong Buy

  • Reply to

    Every Portfolio needs Pran

    by interestingtome Jan 26, 2015 6:53 AM
    kadaicher1 kadaicher1 21 hours ago Flag

    agreed

    Sentiment: Strong Buy

  • Reply to

    Every Portfolio needs to Dump Pran

    by lorde_chatterly Jan 26, 2015 8:50 PM
    kadaicher1 kadaicher1 Jan 26, 2015 8:53 PM Flag

    This is a very low price now. There is nothing but blue sky as Pran moves into advanced development of HD, PD, AD and brain cancer MPAC drugs.

    Sentiment: Strong Buy

  • Reply to

    Sell-off tomorrow?

    by goldbug454 Jan 26, 2015 5:15 PM
    kadaicher1 kadaicher1 Jan 26, 2015 8:49 PM Flag

    A member since Jan21 2015. Could be you know jack.

    Sentiment: Strong Buy

  • Reply to

    Iron chelation, cancer and neurodegeration

    by interestingtome Jan 23, 2015 10:27 PM
    kadaicher1 kadaicher1 Jan 26, 2015 6:28 PM Flag

    Not much chance of that boustrophe, it is an analog of the antibiotic CQ.

    It has been done before, but I don't see PBT2 there.
    "The last-ditch efforts by biotech developer Neurochem Inc. (NRMX) to salvage some value from the US$150-million it has sunk into failed Alzheimer’s disease treatment Alzhemed played out last week like the Monty Python Dead Parrot sketch. Abandoning any further work to prove Alzhemed works according to the scientific standards of the food and drug regulators (which have so far branded results from human clinical trials as “inconclusive”), Laval, Qc.-based Neurochem plans to launch it as an off-the-shelf, unregulated “nutraceutical” to compete with such wonder non-drugs as Gingko Biloba."

    Alzhemed was a natural product and there was not enough patent left to continue development. They had no other way forward. That is not the case with PBT2.
    Neurochem floated Bellus to market it as Vivimind. Here is the latest outcome.

    As part of the transaction, BELLUS Health has licensed the worldwide rights to VIVIMIND™ to FB Health S.p.A. ("FB Health") for a cash consideration of more than $2 million representing a premium of four times VIVIMIND™ revenues generated in 2012".

    Sentiment: Strong Buy

  • Reply to

    10,000 shares at the ask!

    by goldbug454 Jan 26, 2015 5:37 PM
    kadaicher1 kadaicher1 Jan 26, 2015 6:07 PM Flag

    Maybe it is a short. Who cares?

    Sentiment: Strong Buy

  • Reply to

    PRAN

    by cvackerson Jan 26, 2015 5:43 PM
    kadaicher1 kadaicher1 Jan 26, 2015 6:02 PM Flag

    Diehards who recently cashed out some 900% profits and getting ready to do it again. You are here trying to squeeze a few pennies from a small biotech. I think it is plain who is the loser here.

    Sentiment: Strong Buy

  • Reply to

    Every Portfolio needs Pran

    by interestingtome Jan 26, 2015 6:53 AM
    kadaicher1 kadaicher1 Jan 26, 2015 5:56 PM Flag

    Sure, and there are some dangers with straight iron chelation.
    "Immediate symptoms of adverse reaction to IV iron chelation therapy might include: visual disturbances, blurred vision, rash or hives, itching, vomiting, diarrhea, stomach or leg cramps, fever, rapid heart beat, hypotension (low blood pressure), dizziness, anaphylactic shock, and pain or swelling at site of intravenous entry. Long term problems might include kidney or liver damage, loss of hearing or cataracts. "
    Now there is a possibility PBT434 could compete with a drug approved in the USA in 2011 called Ferriprox. In the trial half of patients saw at least 20% reduction in serum ferritin. Ferriprox has an advantage over earlier chelators in that it is orally available, like PBT434.
    When BMP Sunstone announced the move of Ferriprox into China, they estimated a market of 15 million patients in PRC alone.
    "Ferriprox(R) treats iron overload in the bloodstream which is often associated with thalassemia, a disease that can lead to organ damage and heart failure" It is sold in 50 countries. Being also orally available, maybe PBT434 can provide strong competition outside the neurodegeration space. Lets see what comes out.

    Sentiment: Strong Buy

  • Reply to

    Sell-off tomorrow?

    by goldbug454 Jan 26, 2015 5:15 PM
    kadaicher1 kadaicher1 Jan 26, 2015 5:20 PM Flag

    No

    Sentiment: Strong Buy

  • Reply to

    Iron chelation, cancer and neurodegeration

    by interestingtome Jan 23, 2015 10:27 PM
    kadaicher1 kadaicher1 Jan 26, 2015 5:19 PM Flag

    " blood brain barrier penetrant 8-hydroxyquinazolinone compounds was developed."
    Thanks ITM. I have not seen any claims from other iron chelators regarding reduction of a-syn in Parkinson's.
    There are iron chelation drugs out there for iron overload, for instance, in patients who have had many transfusions, but there are dangers.

    Sentiment: Strong Buy

  • Reply to

    Every Portfolio needs Pran

    by interestingtome Jan 26, 2015 6:53 AM
    kadaicher1 kadaicher1 Jan 26, 2015 5:05 PM Flag

    So we already know modulation of iron would have a positive effect in neurodegeneration. Very interesting with PBT434, the iron MPAC arriving in the clinic shortly.
    As I remember the small sample Dr Rosas checked for iron in Reach2HD did not see any change. Seems there could be even stronger HD results with good synergy between MPACs already demonstrated in the lab in the yeast model.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jan 26, 2015 4:47 PM Flag

    ITM is correct. The Rember trial did turn urine and eyes blue. That in mind, it was not even a blinded trial. It was not a genuine blinded trial and the drug they took into ph3, LMTX was different to Rember from the phase2. The difference is that LMTX will not turn eyes blue. TauRx were able to convince the FDA LMTX is virtually the same as Rember. I must admit I thought that was a good move from the FDA not to hold up development at such a critical time.This will be the first blinded trial.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jan 26, 2015 4:37 PM Flag

    Bio, Prana have been very clear from before the IMAGINE and Reach2HD trials began, that the HD application would be first into trials. That was before trials, not just before results. Dr Shoulson has joined the board to make sure PBT2 development reaches its maximum potential in HD, as stated by Dr Shoulson. That in mind, Prana is proceeding just as you recommend, and always has been.
    PBT2 has demonstrated tau protection and tau tangle removal in the model. TauRx also removes tau, but they are not checking for that in this trial as far as I have seen. LMTX may or may not effect cognition in AD, but over 2 years PBT2 may also do it.
    Prana is a company developing drugs in HD, PD, glioblastoma and AD. No way Prana will drop AD. They have increased dosing, combinations, longer time, larger higher powered trials to try.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jan 25, 2015 11:40 AM Flag

    " So can you post where in the annual report? Sec filings? Prana PR reports? Can you or this just pumper remarks or can you prove it?" GY, what does this passage mean? Do you want somebody else to find some information for you?

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jan 25, 2015 11:31 AM Flag

    Or longs sold enough on the last run up to be free riding with a nice profit as well. Of course, if you sell low and buy high, like you seem to think people should do, it is hard to make a profit. Many longs know what is coming and quietly accumulating. Prana always makes a profit from this level, yet you seem to think this incredible buying opportunity is a bad thing for investors. I am very comfortable with my investment for a few reasons. On of them is the J curve in basher activity.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jan 25, 2015 11:23 AM Flag

    Walking it down with smoke and mirrors then. I think you give these clowns too much credit. Maybe it is market makers. I have had the same happen to me. Try to buy a parcel of stock an there are none available for me.
    Last time the bashers were all over this the stock flew shortly after.

    Sentiment: Strong Buy

PRAN
1.38-0.04(-2.82%)Jan 27 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Apple Inc.
NASDAQTue, Jan 27, 2015 4:00 PM EST
Microsoft Corporation
NASDAQTue, Jan 27, 2015 4:00 PM EST
Yahoo! Inc.
NASDAQTue, Jan 27, 2015 4:00 PM EST